美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Hemab Therapeutics Holdings, Inc.

28.76

-0.3950-1.36%

盤後：28.760.00000.00%16:10 EDT

成交量：13.50萬

成交額：399.19萬

市值：13.43億

市盈率：-18.84

高：30.90

開：29.15

低：27.69

收：29.15

52周最高：36.61

52周最低：23.00

股本：4,670.54萬

流通股本：1,675.00萬

量比：0.22

換手率：0.81%

股息：- -

股息率：- -

每股收益(TTM):-1.5260

每股收益(LYR):-67.5613

淨資產收益率：-46.99%

總資產收益率：-30.11%

市淨率：-7.60

市盈率(LYR):-0.43

資料載入中...

總覽公司新聞公告

H.C. Wainwright 首次覆蓋 Hemab Therapeutics，給予「買入」評級及40美元目標價

美國研究綜述-阿波羅、菲利普斯66、瓦萊羅能源

諾和諾德基金會參投的生物科技公司Hemab(COAG.US)擬赴美IPO，最高募資2.12億美元

Hemab Therapeutics Holdings Inc提交SEC文件：預計IPO股價區間為16-18美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/COAG/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"COAG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COAG\",,,,,undefined,":{"symbol":"COAG","market":"US","secType":"STK","nameCN":"Hemab Therapeutics Holdings, Inc.","latestPrice":28.755,"timestamp":1782331200000,"preClose":29.15,"halted":0,"volume":134975,"hourTrading":{"tag":"盘后","latestPrice":28.755,"preClose":28.755,"latestTime":"16:10 EDT","volume":370,"amount":10639.35,"timestamp":1782331805137,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01355060034305316,"floatShares":16750000,"shares":46705400,"eps":-1.526,"marketStatus":"盤後交易","change":-0.395,"latestTime":"06-24 18:57:12 EDT","open":29.15,"high":30.9001,"low":27.6872,"amount":3991883,"amplitude":0.11022,"askPrice":29.32,"askSize":68,"bidPrice":28.2,"bidSize":70,"shortable":0,"etf":0,"ttmEps":-1.526,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1782345600000},"marketStatusCode":4,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":29.15,"preHourTrading":{"tag":"盘前","latestPrice":29.1,"preClose":29.15,"latestTime":"09:29 EDT","volume":147,"amount":4275.230253,"timestamp":1782307799999,"change":-0.05,"changeRate":-0.001715,"amplitude":0.022298},"postHourTrading":{"tag":"盘后","latestPrice":28.755,"preClose":28.755,"latestTime":"16:10 EDT","volume":370,"amount":10639.35,"timestamp":1782331805137,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.224952},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COAG\",,,,,undefined,":{"symbol":"COAG","floatShares":16750000,"roa":"-30.11%","roe":"-46.99%","lyrEps":-67.56131,"volumeRatio":0.224952,"shares":46705400,"dividePrice":0,"high":30.9001,"amplitude":0.11022,"preClose":29.15,"low":27.6872,"week52Low":23.0001,"pbRate":"-7.60","week52High":36.61,"institutionHeld":0,"latestPrice":28.755,"committee":0.014493,"eps":-1.526,"divideRate":0,"volume":134975,"delay":0,"ttmEps":-1.526,"open":29.15,"prevYearClose":18,"prevWeekClose":29.24,"prevMonthClose":28.5,"prevQuarterClose":18,"fiveDayClose":25.51,"twentyDayClose":27.84,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/COAG\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"COAG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"COAG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1781755200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/COAG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"COAG","date":"2026-06-23","current":-18.843381,"percent":0.028571,"low":-23.509442,"twenty":-19.409118,"median":-18.1403,"eighty":-17.49379,"high":-11.042152,"avg":-18.357906,"sd":1.819148,"marketCap":1402682963},"quantilePoints":[{"date":"2026-05-01","current":-11.042152,"twenty":-11.042152,"median":-11.042152,"eighty":-11.042152,"marketCap":705737088},{"date":"2026-05-08","current":-17.79803,"twenty":-17.79803,"median":-17.407359,"eighty":-17.286354,"marketCap":1137525503},{"date":"2026-05-15","current":-19.616555,"twenty":-19.616555,"median":-17.521449,"eighty":-17.286354,"marketCap":1253752856},{"date":"2026-05-22","current":-18.185245,"twenty":-19.409118,"median":-17.853347,"eighty":-17.293269,"marketCap":1162273533},{"date":"2026-05-29","current":-19.360717,"twenty":-19.450605,"median":-18.046954,"eighty":-17.354117,"marketCap":1237401480},{"date":"2026-06-05","current":-17.56985,"twenty":-19.450605,"median":-18.185245,"eighty":-17.491025,"marketCap":1122941843},{"date":"2026-06-12","current":-18.627775,"twenty":-19.370397,"median":-18.1403,"eighty":-17.515917,"marketCap":1190556995},{"date":"2026-06-18","current":-18.288963,"twenty":-19.294337,"median":-18.002009,"eighty":-17.444006,"marketCap":1168902469},{"date":"2026-06-23","current":-21.946755,"twenty":-19.409118,"median":-18.1403,"eighty":-17.49379,"marketCap":1402682963}],"updateTime":1782335427167},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"COAG\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1183732399","title":"H.C. Wainwright 首次覆蓋 Hemab Therapeutics，給予「買入」評級及40美元目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=1183732399","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183732399?lang=zh_tw&edition=fundamental","pubTime":"2026-06-17 18:08","pubTimestamp":1781690902,"startTime":"0","endTime":"0","summary":"投资机构 H.C. Wainwright 近日启动了对 Hemab Therapeutics Holdings, Inc. 的研究覆盖，并给予了“买入”评级。该机构为这家生物技术公司设定了每股40美元的目标价格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638473599","title":"美國研究綜述-阿波羅、菲利普斯66、瓦萊羅能源","url":"https://stock-news.laohu8.com/highlight/detail?id=2638473599","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638473599?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 15:32","pubTimestamp":1779780727,"startTime":"0","endTime":"0","summary":"美国研究综述-阿波罗、菲利普斯66、瓦莱罗能源路透5月26日 - 周二，华尔街证券分析师调整了多家在美国上市公司的评级和目标股价，其中包括阿波罗、菲利普斯66和瓦莱罗能源。股票条目按字母顺序排列。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nL4T4230EH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4138","LU0477156953.USD","TKR","LU1201861249.SGD","HLIO","LU1803068623.USD","LU1861214812.USD","LU2106854487.HKD","LU0170899867.USD","BK4157","SPTX","LU0266512473.USD","COAG","RRX","LU0130517989.USD","TDS","IE00B19Z3581.USD","LU0456854461.SGD","MPC","CGNX","LU0266013472.USD","BAH","BK4139","LU0630314457.HKD","VLO","LU0980610538.SGD","APO","TTAN","LU0300736062.USD","LU1169589451.USD","BK4548","ALBG","LU0096364046.USD","LU1206713676.USD","BK4155","LU0266512127.USD","IE00BZ1G4Q59.USD","BK4161","IE00B775SV38.USD","ALB","LU0205194284.USD","LU0345780950.USD","LU2095319765.USD","PS","BJ","BK4585","AD","LU0274383776.USD","PSX","ALNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630437375","title":"諾和諾德基金會參投的生物科技公司Hemab(COAG.US)擬赴美IPO，最高募資2.12億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630437375","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630437375?lang=zh_tw&edition=fundamental","pubTime":"2026-04-28 16:00","pubTimestamp":1777363239,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，临床阶段生物科技公司Hemab Therapeutics Holdings Inc.正寻求在美国首次公开募股中最高融资2.12亿美元。此次生物科技公司IPO的背景是，投资者对减肥药物开发商Kailera Therapeutics Inc.给予了热烈反响——该公司于本月初上市，募资7.19亿美元，创下2021年以来该行业在美国最大的IPO记录。招股文件还显示，在本次发行前，RA Capital Management的关联实体与诺和诺德基金会分别持有Hemab 18%和15%的股份。截至2025年12月31日，公司持有现金及现金等价物共1.85亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4532","BK4588","IE00BZ1G4Q59.USD","BK4599","LU0154236417.USD","BK4585","IE00BKVL7J92.USD","NVO","NVOH","COAG","BK4007","BK4581","LU1093756168.USD","NVOX","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195572245","title":"Hemab Therapeutics Holdings Inc提交SEC文件：預計IPO股價區間為16-18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1195572245","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195572245?lang=zh_tw&edition=fundamental","pubTime":"2026-04-27 19:22","pubTimestamp":1777288965,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，生物制药公司Hemab Therapeutics Holdings Inc首次公开募股（IPO）的初步定价区间已确定为每股16美元至18美元。\n这一价格区间标志着该公司正式迈出登陆公开资本市场的关键一步。若按此区间上限计算，此次IPO有望为Hemab Therapeutics募集可观的资金，用于推进其创新疗法的研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}